Clinical Study Synopsis

Size: px
Start display at page:

Download "Clinical Study Synopsis"

Transcription

1 Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayer.com apply to the contents of this file.

2 Study no Page: 1 of 8 Date of study report: 30 Apr 2018 Study title: Sponsor s study number: NCT number: EudraCT number: Sponsor: Clinical phase: Study objectives: REGO-ACT, Assessment of physical activity during therapy with regorafenib for metastatic colorectal cancer NCT Not Applicable Bayer Non-interventional Primary Objective: To assess the average amount of physical activity of patients with mcrc during regorafenib treatment as measured using pedometer data and International Physical Activity Questionnaire (IPAQ) results. The primary endpoints were the amount of physical activity during regorafenib treatment based on: Median number of steps/day measured on a 1-week basis (i.e., from Days 1 7) as well as for additional 1-week intervals through the end of the study using a pedometer Median number of steps/day measured on a 4-week basis (i.e., from on Days 1 28) as well as for additional 4-week intervals through the end of the study using a pedometer International Physical Activity Questionnaire (IPAQ) score on Days 28, 56, and 84 in metabolic equivalents of a task (MET) minutes/week Delta IPAQ between Days 1 and 28, Days 1 and 56, and Days 1 and 84 in MET minutes/week Secondary Objectives: Potential secondary objectives of this study were to assess the relation between the level of physical activity on the one hand and quality of life (QoL, as assessed using the EQ-5D-3L questionnaire), the frequency of the adverse event (AE) fatigue, disease control rate (DCR), progressionfree survival (PFS), and overall survival (OS) on the other. The secondary endpoints were the relation between physical activity (in terms of both the median number of steps/day and MET minutes/week) and

3 Study no Page: 2 of 8 QoL of life as measured by the EQ-5D-3L in CORRELATE (NCT , Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings ) Incidence of the AE fatigue as reported in CORRELATE DCR, defined as the percentage of patients whose best response was a complete response (CR), partial response (PR), or stable disease (SD); stable disease must have been at least 6 weeks in duration as assessed in CORRELATE. PFS, defined as the time from the date of the first regorafenib dose to the date of progressive disease (PD) or death as estimated by the Kaplan-Meier method observed in CORRELATE OS, defined as the time from the start of regorafenib therapy to the date of death in CORRELATE. Patients who had not died by the analysis cut-off date were censored at their last contact date (Kaplan-Meier method) in CORRELATE. Test drug: Name of active ingredient(s): Dose: Route of administration: Duration of treatment: Reference drug: Indication: Diagnosis and main criteria for inclusion: Regorafenib (Stivarga, BAY ) Regorafenib Treatment was done according to the label approved by EMA. The recommended dose of regorafenib is 160 mg taken once daily for 3 weeks, followed by 1 week off therapy. In this study, dosing decisions were at the discretion of the treating physicians. Oral The planned observation period for each patient enrolled into the study was 3 months (84 days) from enrolment into REGO-ACT to the end of REGO-ACT, regorafenib treatment, withdrawal of consent, or death, whichever occurred first. Not Applicable Metastatic Colorectal cancer Only patients included into CORRELATE in Austria may participate in this local study. Inclusion criteria of OS CORRELATE: Patients had been diagnosed with mcrc who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom a treatment

4 Study no Page: 3 of 8 Study design: Methodology: Study center(s): Publication(s) based on the study (references): decision in favor of regorafenib had been made per investigator s routine treatment practice. had given signed informed consent for enrolment into CORRELATE. Inclusion criteria of REGO-ACT: Patients enrolled in CORRELATE in Austria Signed patient informed consent for enrolment into REGO-ACT This is a local, prospective, non-interventional, multi-center, single arm pilot study All study sites participating in and enrolling patients into the international non-interventional CORRELATE study were offered participation in REGO-ACT. The purpose of the CORRELATE study was to investigate the safety and effectiveness of regorafenib in routine clinical practice. Overall, 5 Austrian study sites participated in this study. All of the 25 patients enrolled into this study had initially been enrolled into CORRELATE. Subjects filled in the International physical activity questionnaire at baseline, and then at each visit according to physician s discretion (following time schedule is recommended: every 28 days up to 84 days from enrolment into REGO-ACT to the end of REGO-ACT, regorafenib treatment, withdrawal of consent, or death, whichever occurred first). Additionally, for objective measurement of physical activity all patients received a CE-certified pedometer at baseline. The pedometer should be worn for 84 days from enrolment into REGO-ACT to the end of REGO-ACT, regorafenib treatment, withdrawal of consent, or death, whichever occurred first. Data capture of the pedometer will be performed at each visit. The aim is to quantitatively evaluate the amount of physical activity in this patient population. 5 study sites in Austria None at the time of report creation Study period: Study Start Date: 20-Jan-2015 Study Completion Date: 08-Sep-2016 Early termination: No

5 Study no Page: 4 of 8 Number of subjects: Planned: 25 Criteria of evaluation: Efficacy: Safety: Statistical methods: Substantial protocol changes: Analyzed: 25 Primary: The number of steps/day as measured using a pedometer The self-administered International Physical Activity Questionnaire (IPAQ) MET minutes/week as recorded in the REGO-ACT study. Secondary: the relation between physical activity (in terms of both the median number of steps/day and MET minutes/week) and QoL of life as measured by the EQ-5D-3L in CORRELATE Incidence of the AE fatigue as reported in CORRELATE DCR, defined as the percentage of patients whose best response was a complete response (CR), partial response (PR), or stable disease (SD); stable disease must have been at least 6 weeks in duration as assessed in CORRELATE. PFS, defined as the time from the date of the first regorafenib dose to the date of progressive disease (PD) or death as estimated by the Kaplan- Meier method observed in CORRELATE OS, defined as the time from the start of regorafenib therapy to the date of death in CORRELATE. Patients who had not died by the analysis cutoff date were censored at their last contact date (Kaplan-Meiermethod) in CORRELATE. Adverse events All data were analyzed using descriptive statistics. Study was conducted according to final study protocol dated 02 Jan 2015 and included no substantial amendments Subject disposition and baseline Of the 25 patients enrolled, 16 patients (64%) were male and 9 patients (36%) were female. The mean age was 62.4±10.9 years (range, years).

6 Study no Page: 5 of 8 Efficacy evaluation [Primary]: Median number of steps/day Pedometer data were available for 22 of the 25 enrolled patients. The number of days with available pedometer data varied widely among the 22 patients, ranging from 6 to 100. In individual patients, the number of days with pedometer data slightly exceeded the number of days of study participation, with some patients returning the pedometer after the official study end and still wearing the pedometer during this time. Of the 11 patients who participated in the study for the entire scheduled duration of 84 days, 3 patients had pedometer results for 82, 84, and 100 days, 13 patients had pedometer data for days, and 6 patients had pedometer data for 6 13 days. A total of 16 patients had pedometer data for at least 21 days. The median number of steps/day measured on a 1-week and 4-week basis remained relatively constant throughout the course of the study. However, wide variations between the minimum and maximum numbers of steps were seen (e.g., between 31 and 8131 steps/day on Days 1 7). From this analysis, it was unclear whether these were intra- or interindividual variations. Therefore, we also specifically looked at the step counts of each individual patient. When looking at patients individually, considerable variations were seen in the weekly and monthly median number of steps/day, particularly between patients. Interindividually, baseline median step counts/day on a 1-week basis ranged between 31 and When only patients with at least 3 weeks of available pedometer data were looked at (n=16), the baseline median number of steps/day on a 1- week basis ranged from 130 to 7239; 13 of these 16 patients had step counts above 1200, thus being well within the range reported for special populations in the literature. Intraindividually, median step counts on a 1-week basis varied over time in some patients, but remained relatively constant in others. To better understand the intra- and interindividual variations in the median number of steps/day seen at a 1-week basis, daily step counts per patient were also analyzed. Intraindividually, step counts/day in some patients varied by several thousands of steps/day, e.g., from 10 to 10,934 in one patient or from 2,093 to 14,931 in another patient). Interindividually, maximum step counts/day varied between 401 and 14,931. Although intraindividual step counts varied considerably on a day-to-day basis, the median number of steps/day analyzed on a 1-week basis appears to provide a good indication of a patient s general level of activity, with weekly step counts in the range of several thousands in some and several hundreds in other patients.

7 Study no Page: 6 of 8 IPAQ results Of the 25 patients, 21 patients completed the IPAQ questionnaire at least once. During data analysis, it was found that many completed questionnaires were not directly evaluable because of implausible or incomplete responses. As a result of these inconsistencies, only a minority of completed IPAQs were considered to have yielded reliable results. At the same time, visit intervals varied considerably between patients, and the number of patients with available IPAQ results dropped throughout the course of the study. The primary endpoints including IPAQ results were therefore considered to defy reliable statistical analysis. [Secondary]: The relation between physical activity and other variables was analyzed only on the basis of the median number of steps/day, but not on the basis of IPAQ results. Relation between the median number of steps/day and QoL as measured using the EQ-5D-3L in CORRELATE To determine the relation between the median number of steps/day and QoL as measured by the EQ- 5D-3L, only EQ-VAS values were used. At the beginning of the study, moderately strong correlations between EQVAS and the median number of steps/day on Days 1 7 and 8 14 were seen. Moderately strong correlations between EQ-VAS and the median number of steps/day on Days 8 14 and were also found at time point 3 of EQ-VAS assessment. Relation between step counts and the incidence of the AE fatigue as reported in CORRELATE Of the 25 enrolled patients, 14 patients (56%) reported fatigue in the course of the CORRELATE study. Of these 14 patients, 10 patients experienced fatigue during the course of the REGO-ACT study, and only 8 patients reported fatigue within their individual time periods of pedometer use. No significant correlations between the median number of steps/day and the presence of fatigue were found. Overall, however, patient numbers were too small and periods of observation too short to draw statistically reliable conclusions on the correlation between step counts and fatigue. Relation between the median number of steps/day and DCR, PFS, or OS as reported in CORRELATE Due to rapidly decreasing numbers of patients with pedometer data throughout the course of REGO- ACT, the high intra- and interindividual variations in step counts, and still incomplete CORRELATE response data at the end of the REGO-ACT study, correlations between the median number of steps/day and DCR, PFS, and OS could not reliably be determined. However, looking at patients individually, relations between step counts and DCR, PFS, or OS appear unlikely, with some patients displaying comparatively high levels of walking activity almost up to the time of their

8 Study no Page: 7 of 8 disease progression or death and other patients showing very low levels or short durations of walking activity despite comparatively high levels of QoL or longer survival. Safety evaluation To avoid duplicate reporting, safety reporting was performed as part of the CORRELATE study only. Overall conclusions The primary aim of this pilot study was to obtain data on the extent of physical activity of patients with mcrc during regorafenib therapy. The study showed that, despite the severity of their disease, patients generally displayed remarkable levels of walking activity, with baseline levels in most patients within the range for special populations reported in the literature. In view of the widely differing baseline levels of walking activity between patients, the aim of exercise programs for the special patient population included in this study should be to tailor interventions to the specific needs, physical capacity, and preferences of each individual patient rather than prescribing normative stepcount targets for the entire population. While the pedometer results of this study established a baseline step count for the majority of our patients, a number of factors most importantly technical issues related to step counting and the lack of patient supervision due to the non-interventional nature of this study limited the utility of the pedometer in measuring long-term physical activity levels in this study and should be addressed in future research. The key limitations of this pilot study were its small sample size and its non-interventional character, which resulted in a relatively large proportion of missing data, widely varying visit intervals, implausible IPAQ entries, and ultimately only 3 patients with pedometer results spanning the entire 84-day observation period scheduled for the study. In view of these limitations, some of the predefined endpoints may have been too specific or complex and were ultimately not analyzable as originally planned. For example, completing the IPAQ, a tool also used in this study to estimate the patients level of physical activity, appeared to have been too demanding to complete for many patients, and future studies may benefit from simpler tools to document patient-reported levels of exercise. By contrast, the EQ-5D-3L questionnaire used in this study to measure the patients QoL is a concise and easyto-use tool, and its EQ-VAS component was the only variable in this study to show moderate correlations with the pedometer data obtained, and the relations between step counts and measures of subjective well-being therefore clearly warrant additional research. One focus of this study was on a common side effect of treatment with regorafenib, i.e., fatigue, which can markedly affect a patient s well-being and interfere with daily life. Available evidence suggests that physical exercise is beneficial for cancer patients and may mitigate cancer-related fatigue. Although this pilot study did not find a correlation between fatigue and walking activity, this may, at least in part, have been due the methodological aspect of fatigue having been reported as an AE during follow-up visits rather than being more closely and consistently monitored throughout the study, preferably on a daily basis. Therefore, future research may benefit from the use of tools

9 Study no Page: 8 of 8 specifically developed to closely monitor fatigue. In addition, other AEs, such as pain, diarrhea, vertigo, dyspnea, or palmar-plantar erythrodysesthesia, may also have an effect on a patient s ability or willingness to exercise and merit inclusion in future studies. Overall, the preliminary data on the individual levels of walking activity of mcrc patients and the methodologically insights from this pilot study can serve as a starting point for the development of tailored exercise prescription programs designed to alleviate cancer-related side effects and improve patient well-being and quality of life.

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

EMERGENCY USE 03/02/2016

EMERGENCY USE 03/02/2016 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program EMERGENCY USE 03/02/2016 Emergency Exemption for an Investigational Drug or Biologic or Unapproved Device Emergency use of an investigational

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Human, Recombinant) Reference Number: CP.CPA.76 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of

More information

SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS

SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS University of Oklahoma Office of Human Research Participant Protection : PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS 1. POLICY Protocol deviations and unanticipated problems may be discovered in a variety

More information

Natural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone

Natural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured

More information

IRB Training October 22, 2015

IRB Training October 22, 2015 Humanitarian Use Devices & Humanitarian Device Exemptions IRB Training October 22, 2015 What is a Humanitarian Use Device (HUD)? Intended to benefit patients in the treatment or diagnosis of diseases or

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Page 1 of 6 POLICY CONTINUING REVIEW BY THE IRB The University of Cincinnati Institutional Review Board (IRB) shall conduct continuing review of human participant research at intervals appropriate to the

More information

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH I. PURPOSE This document outlines the University of Tennessee Health Science Center Institutional

More information

AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016

AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016 The Duke University Health System Institutional Review Board (DUHS IRB) requires that

More information

Date Effective 4/21/2008 Identification

Date Effective 4/21/2008 Identification OHSU Research Integrity Office Human Research Protection Program Policies & Procedures Title: Research with Medical Devices Date Effective 4/21/2008 Identification Supersedes P&P dated: Page 1 of BACKGROUND

More information

Second Quarter 2018 Results Call Corporate Update & Financial Results. August 7, 2018

Second Quarter 2018 Results Call Corporate Update & Financial Results. August 7, 2018 Second Quarter 2018 Results Call Corporate Update & Financial Results August 7, 2018 Forward-Looking Statements BioCryst s presentation may contain forward-looking statements, including statements regarding

More information

THERAPEUTIC USE EXEMPTION POLICY U.S. ANTI-DOPING AGENCY. Effective JANUARY 1, (Revised June 21, 2018)

THERAPEUTIC USE EXEMPTION POLICY U.S. ANTI-DOPING AGENCY. Effective JANUARY 1, (Revised June 21, 2018) THERAPEUTIC USE EXEMPTION POLICY U.S. ANTI-DOPING AGENCY Effective JANUARY 1, 2018 (Revised June 21, 2018) 1. GENERAL PRINCIPLES The United States Anti-Doping Agency ( USADA ) Policy for Therapeutic Use

More information

SFHCHS78 Administer oxygen safely and effectively

SFHCHS78 Administer oxygen safely and effectively Overview This standard is about the safe and effective administration of oxygen in all healthcare settings, at home and in any environment where an individual requires oxygen therapy. Users of this standard

More information

SOP Title Review of Research: Devices for Humanitarian Uses

SOP Title Review of Research: Devices for Humanitarian Uses SOP Title Review of Research: Devices for Humanitarian Uses Purpose This document describes the National Jewish Health IRB review of Humanitarian Use Devices and Humanitarian Device Exemptions. Scope Humanitarian

More information

Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013; 05/01/2016; 10/16/2018

Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013; 05/01/2016; 10/16/2018 University of California, Irvine Human Research Protections Standard Operating Policies and Procedures Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013;

More information

7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL

7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL 7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL 7.1 OBJECTIVE To describe the policies and procedures for reviewing a modification or a deviation/exception to a previously approved protocol.

More information

2019 Canada Winter Games Synchronized Swimming Technical Package

2019 Canada Winter Games Synchronized Swimming Technical Package 2019 Canada Winter Games Synchronized Swimming Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility

More information

The Effect of a Seven Week Exercise Program on Golf Swing Performance and Musculoskeletal Screening Scores

The Effect of a Seven Week Exercise Program on Golf Swing Performance and Musculoskeletal Screening Scores The Effect of a Seven Week Exercise Program on Golf Swing Performance and Musculoskeletal Screening Scores 2017 Mico Hannes Olivier Bachelor of Sport Science Faculty of Health Sciences and Medicine Bond

More information

Independent Ethics Committees

Independent Ethics Committees GCP Independent Ethics Committees 1 GCP What is an Ethics Committee? An ethics committee is a committee formally designated to review and approve the initiation of a clinical research study involving human

More information

Eustachian Tube Dysfunction Patient Questionnaire (ETDQ-7) Collection, Training and Utility

Eustachian Tube Dysfunction Patient Questionnaire (ETDQ-7) Collection, Training and Utility Eustachian Tube Dysfunction Patient Questionnaire (ETDQ-7) Collection, Training and Utility 2017 Acclarent, Inc. All rights reserved. 070561-170405 1 ETDQ-7: What is it? The ETDQ-7 is a disease-specific

More information

Study Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB)

Study Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB) Study Management SM 302.00 STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval:

More information

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH I. PURPOSE This document outlines the required elements of University of Tennessee

More information

Yale University Human Research Protection Program

Yale University Human Research Protection Program Yale University Human Research Protection Program HRPP Policy 700 Noncompliance, Suspension and Termination Responsible Office Office of Research Administration Effective Date: February 10, 2009 Responsible

More information

Flip-flop footwear with a moulded foot-bed for the treatment of foot pain: a randomised controlled trial

Flip-flop footwear with a moulded foot-bed for the treatment of foot pain: a randomised controlled trial Flip-flop footwear with a moulded foot-bed for the treatment of foot pain: a randomised controlled trial Dr. Martin Spink, Ms. Angela Searle and Dr. Vivienne Chuter Podiatry department Faculty of Health

More information

CONTINUING REVIEW 3/7/2016

CONTINUING REVIEW 3/7/2016 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program Introduction CONTINUING REVIEW 3/7/2016 Federal regulations require that DUHS has written procedures which the IRB will follow for (a) conducting

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia: a Randomized Clinical Trial.

More information

Current Status: Active PolicyStat ID: Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021

Current Status: Active PolicyStat ID: Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021 Current Status: Active PolicyStat ID: 4870880 Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021 Owner: Policy Area: References: Suzanne Sharland-Hemmila:

More information

2010 TRAVEL TIME REPORT

2010 TRAVEL TIME REPORT CASUALTY ACTUARIAL SOCIETY EDUCATION POLICY COMMITTEE 2010 TRAVEL TIME REPORT BIENNIAL REPORT TO THE BOARD OF DIRECTORS ON TRAVEL TIME STATISTICS FOR CANDIDATES OF THE CASUALTY ACTUARIAL SOCIETY June 2011

More information

OHRP Guidance on Written IRB Procedures

OHRP Guidance on Written IRB Procedures Office for Human Research Protections (OHRP) Department of Health and Human Services Date: OHRP Guidance on Written IRB Procedures Scope: This document outlines the required elements of written Institutional

More information

2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE

2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE 2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and

More information

M0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:

M0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR: M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in

More information

JEPonline Journal of Exercise Physiologyonline

JEPonline Journal of Exercise Physiologyonline Walking Technique and Estimated VO 2 max Values 21 JEPonline Journal of Exercise Physiologyonline Official Journal of The American Society of Exercise Physiologists (ASEP) ISSN 1097-9751 An International

More information

2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE

2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE 2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and

More information

Wayne State University Institutional Review Board

Wayne State University Institutional Review Board Wayne State University Institutional Review Board Subject Approvals, Serious & Continuing Non-Compliance and the Institutional Official s Responsibilities Administrative Approval: 07/2011; Office of the

More information

Effective Date: January 16, 2012 Policy Number: MHC_RP0107. Revised Date: November 2, 2015 Oversight Level: Corporate

Effective Date: January 16, 2012 Policy Number: MHC_RP0107. Revised Date: November 2, 2015 Oversight Level: Corporate Policy Title: Initial Review of Human Subject Research Effective Date: January 16, 2012 Policy Number: Review Date: November 20, 2015 Section: Revised Date: November 2, 2015 Oversight Level: Corporate

More information

The Impact of TennCare: A Survey of Recipients 2009

The Impact of TennCare: A Survey of Recipients 2009 The Impact of TennCare: A Survey of Recipients 2009 Christopher Carty Research Associate, Center for Business and Economic Research William F. Fox Director, Center for Business and Economic Research and

More information

Baptist Health Institutional Review Board. Study Closure Report (Expedited Review) IRB #: Study Title:

Baptist Health Institutional Review Board. Study Closure Report (Expedited Review) IRB #: Study Title: Baptist Health Institutional Review Board Study Closure Report (Expedited Review) (Please complete ALL sections of this form. Incomplete forms will be returned) Principal Investigator: E-mail: Phone #:

More information

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride 1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride

More information

Humanitarian Use Devices Made Simple

Humanitarian Use Devices Made Simple May 25, 2017 Humanitarian Use Devices Made Simple Robert Romanchuk, BSHS, CIP, CCRC, CHRC, CCRCP IRB Vice Chairperson, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA

More information

SITE NAME: ISF DOCUMENT VERSION CHECKLIST Complete yes or no to confirm the presence or absence of each document specified.

SITE NAME: ISF DOCUMENT VERSION CHECKLIST Complete yes or no to confirm the presence or absence of each document specified. 1. TRIAL MANAGEMENT CTC Contact List 8 29/07/2016 Y N CTC Contact List (superseded) 7 29/09/2015 Y N CTC Contact List (superseded) 6 24/02/2015 Y N CTC Contact List (superseded) 5 03/09/2014 Y N CTC Contact

More information

2017 Canada Summer Games Indoor Volleyball Technical Package

2017 Canada Summer Games Indoor Volleyball Technical Package 2017 Canada Summer Games Indoor Volleyball Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements,

More information

CONTINUING REVIEW CRITERIA FOR RENEWAL

CONTINUING REVIEW CRITERIA FOR RENEWAL 1. POLICY Steering Committee approved / Effective Date: 9/2/19/19/11 The IRB conducts continuing review of research taking place within its jurisdiction at intervals appropriate to the degree of risk,

More information

Cambridge International Examinations Cambridge Ordinary Level

Cambridge International Examinations Cambridge Ordinary Level Cambridge International Examinations Cambridge Ordinary Level *9399919087* STATISTICS 4040/12 Paper 1 October/November 2015 Candidates answer on the Question Paper. Additional Materials: Pair of compasses

More information

Assessment of Guide Reporting & Preliminary Results of Lion Monitoring

Assessment of Guide Reporting & Preliminary Results of Lion Monitoring Assessment of Guide Reporting & Preliminary Results of Lion Monitoring Mara Predator Project December 21 Sara Blackburn Laurence Frank maralions@gmail.com lgfrank@berkeley.edu SUMMARY The Mara Predator

More information

The Onychomycosis Market (2018 Edition) September 2018

The Onychomycosis Market (2018 Edition) September 2018 The Onychomycosis Market (2018 Edition) September 2018 The US Onychomycosis Market:Coverage Executive Summary and Scope Introduction/Market Overview Global Market Analysis The US Market Analysis Competitive

More information

2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package

2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package 2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility

More information

CSHCN Services Program Prior Authorization Request for Oxygen Therapy Form and Instructions

CSHCN Services Program Prior Authorization Request for Oxygen Therapy Form and Instructions General Information CSHCN Services Program Prior Authorization Request for and Instructions Ensure the most recent version of the Prior Authorization Request for Oxygen Therapy form is submitted. The form

More information

IGEM/TD/2 Edition 2 with amendments July 2015 Communication 1779 Assessing the risks from high pressure Natural Gas pipelines

IGEM/TD/2 Edition 2 with amendments July 2015 Communication 1779 Assessing the risks from high pressure Natural Gas pipelines Communication 1779 Assessing the risks from high pressure Natural Gas pipelines Founded 1863 Royal Charter 1929 Patron: Her Majesty the Queen Communication 1779 Assessing the risks from high pressure Natural

More information

A review of 2015 fatal collision statistics as of 31 December 2015

A review of 2015 fatal collision statistics as of 31 December 2015 A review of fatal collision statistics as of 31 December This report summarises the main trends in road fatalities that have emerged in. This has been prepared by the Road Safety Authority following analysis

More information

Developing very brief interventions (VBIs) to promote physical activity in primary care

Developing very brief interventions (VBIs) to promote physical activity in primary care Walk Walk Developing very brief interventions (VBIs) to promote physical activity in primary care Walk Walk Sally Pears BPS Division of Health Psychology Annual Conference, York 2014 Move Funder: NIHR

More information

RESEARCH PROTECTIONS OFFICE

RESEARCH PROTECTIONS OFFICE Page 1 of 5 RESEARCH PROTECTIONS OFFICE Single IRB RPO Human Subjects Research Single IRB Single IRB Definitions Authorization Agreement/Reliance Agreement written agreement between two or more institutions

More information

NZQA unit standard version 1 Page 1 of 5. Demonstrate knowledge of hazardous substances relevant to Certified Handlers

NZQA unit standard version 1 Page 1 of 5. Demonstrate knowledge of hazardous substances relevant to Certified Handlers Page 1 of 5 Title Demonstrate knowledge of hazardous substances relevant to Certified Handlers Level 5 Credits 6 Purpose This unit standard is for people preparing for, and intend to apply for, Certified

More information

Issue in IRB Approvals:

Issue in IRB Approvals: Issue in IRB Approvals: What are the obligations of investigators and the IRB in maintaining IRB approval? What are the consequences of a lapse in IRB approval? How does the IRB evaluate lapses in approval?

More information

HUMAN SUBJECTS INSTITUTIONAL REVIEW BOARD PROCEDURES

HUMAN SUBJECTS INSTITUTIONAL REVIEW BOARD PROCEDURES 1 HUMAN SUBJECTS INSTITUTIONAL REVIEW BOARD PROCEDURES http://www.sjsu.edu/gradstudies/irb The Institutional Review Board (IRB) is a ten to fifteen member committee whose task is to review all research

More information

Salisbury District Hospital

Salisbury District Hospital The Effectiveness of Peroneal Nerve Functional Electrical STimulation (FES) for the Reduction of Bradykinesia in Parkinson s Disease: A Pragmatic Two Site Feasibility Study for a Single Blinded Randomised

More information

Minot State University Institutional Review Board ANNUAL UPDATE/REVISION/PROJECT COMPLETION REPORT

Minot State University Institutional Review Board ANNUAL UPDATE/REVISION/PROJECT COMPLETION REPORT Minot State University Institutional Review Board ANNUAL UPDATE/REVISION/PROJECT COMPLETION REPORT Annual Updates, Revisions, or Project Completion/Termination Reports should by typed on no more than two

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Arkansas Tech University Institutional Review Board

Arkansas Tech University Institutional Review Board Arkansas Tech University Institutional Review Board Presentation Agenda IRB 1001: The Basics Levels of IRB Review IRB Decisions The Process of Consent Open Discussion IRB 1001: The Basics Human Participant

More information

Coaching Applications The Effect of Intermittent Hypoxic Exposure plus Sea Level Swimming Training on Anaerobic Swimming Performance

Coaching Applications The Effect of Intermittent Hypoxic Exposure plus Sea Level Swimming Training on Anaerobic Swimming Performance J. Swimming Research, Vol. 19:2 (2012) Coaching Applications plus Sea Level Swimming Training on Anaerobic Swimming Performance Miller A.N. 1 and George K. 2 Department of Biomolecular and Sports Science,

More information

Waterford Soccer Club Travel Team Policies

Waterford Soccer Club Travel Team Policies Waterford Soccer Club Travel Team Policies Introduction The following document describes the policies which Waterford Soccer Club (WSC) uses to administer its Travel Soccer program. While the club by-laws

More information

The IRB reviews and monitors human subjects research conducted by Columbia College Chicago faculty, staff, and students.

The IRB reviews and monitors human subjects research conducted by Columbia College Chicago faculty, staff, and students. IRB FAQ s We hope that this FAQ will acquaint you with the basic policies and procedures of the IRB review and approval process. It is available to researchers from the Columbia College Chicago IRB. Although

More information

A. Evaluation of the written program

A. Evaluation of the written program A. Evaluation of the written program Begin your audit with an evaluation of the written respiratory protection program. In addition to the operating procedures describing respirator selection and use in

More information

2019 Canada Winter Games Wheelchair Basketball Technical Package

2019 Canada Winter Games Wheelchair Basketball Technical Package 2019 Canada Winter Games Wheelchair Basketball Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility

More information

UNIVERSITY OF GEORGIA Institutional Review Board

UNIVERSITY OF GEORGIA Institutional Review Board UNIVERSITY OF GEORGIA Institutional Review Board Continuing Review Number: Date: Author: Approved By: Page(s): UGAHRP-057-2 01/20/2017 HSO IRB Page 1 of 7 1. PURPOSE 1.1. The UGA IRB has developed this

More information

Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval

Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval Additional copies are available from: Office of Communication Division of Drug Information,

More information

2017 Canada Summer Games Beach Volleyball Technical Package

2017 Canada Summer Games Beach Volleyball Technical Package 2017 Canada Summer Games Beach Volleyball Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements,

More information

Annapolis Striders Winter Half Marathon Training Program TRAINING UPDATE 06

Annapolis Striders Winter Half Marathon Training Program TRAINING UPDATE 06 Annapolis Striders Winter Half Marathon Training Program TRAINING UPDATE 06 MICHAEL MYERS STRESSORS 02/10/2018 EIGHT-MILES TO JUMPERS AND BACK WITH A THINNER HERD TODAY S RUN On Saturday 10 February, 33

More information

Elements for a Public Summary. Overview of disease epidemiology

Elements for a Public Summary. Overview of disease epidemiology VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases

More information

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc. GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN

More information

2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package

2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package 2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility

More information

CONTINUING REVIEW CRITERIA FOR RENEWAL

CONTINUING REVIEW CRITERIA FOR RENEWAL 1. POLICY Steering Committee approved / Effective Date: 9/2/15 The IRB conducts continuing review of research taking place within its jurisdiction at intervals appropriate to the degree of risk, but not

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute / IRB Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,

More information

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM 750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride

More information

Risk Factors Involved in Cheerleading Injuries

Risk Factors Involved in Cheerleading Injuries University of Arkansas, Fayetteville ScholarWorks@UARK Health, Human Performance and Recreation Undergraduate Honors Theses Health, Human Performance and Recreation 5-2016 Risk Factors Involved in Cheerleading

More information

2017 Canada Summer Games Golf Technical Package

2017 Canada Summer Games Golf Technical Package 2017 Canada Summer Games Golf Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements, assist

More information

HUD and HDE Topics. Humanitarian Use Device and. Humanitarian Use Device. Humanitarian Device Exemption

HUD and HDE Topics. Humanitarian Use Device and. Humanitarian Use Device. Humanitarian Device Exemption Humanitarian Use Device Humanitarian Device Exemption Marian Serge, RN Division of Bioresearch Monitoring Center for Devices and Radiological Health Marian.Serge@fda.hhs.gov 1 HUD and HDE Topics Regulations//Guidance

More information

2015 CANADA WINTER GAMES WHEELCHAIR BASKETBALL TECHNICAL PACKAGE

2015 CANADA WINTER GAMES WHEELCHAIR BASKETBALL TECHNICAL PACKAGE 2015 CANADA WINTER GAMES WHEELCHAIR BASKETBALL TECHNICAL PACKAGE Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility

More information

Reduction of Speed Limit at Approaches to Railway Level Crossings in WA. Main Roads WA. Presenter - Brian Kidd

Reduction of Speed Limit at Approaches to Railway Level Crossings in WA. Main Roads WA. Presenter - Brian Kidd Australasian College of Road Safety Conference A Safe System: Making it Happen! Melbourne 1-2 September 2011 Reduction of Speed Limit at Approaches to Railway Level Crossings in WA Radalj T 1, Kidd B 1

More information

Figure 39. Yearly Trend in Death Rates for Drowning: NSW, Year

Figure 39. Yearly Trend in Death Rates for Drowning: NSW, Year 10.0 DROWNING 10.1 Deaths due to Drowning: The drowning death rate showed a statistically significant decrease between 199 and 1999 (Figure 39). Between 199 and 1999, 46 people died from drowning, at a

More information

2019 Canada Winter Games Freestyle Ski Technical Package

2019 Canada Winter Games Freestyle Ski Technical Package 2019 Canada Winter Games Freestyle Ski Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements,

More information

HEALTH CARE SYSTEMS RESEARCH NETWORK

HEALTH CARE SYSTEMS RESEARCH NETWORK IRB APPROVAL OF HCSRN MULTI-SITE RESEARCH: FREQUENTLY ASKED QUESTIONS (AND ANSWERS) The goal of SOP HCSRN-001,, is to make human subjects review as efficient and timely as possible, while still recognizing

More information

University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP)

University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP) University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP) I. OVERVIEW The purpose of this Standard Operating Procedure is to define a process for all University of Iowa

More information

ARDS Network Investigators Response to the October 7, 2002 OHRP Letter

ARDS Network Investigators Response to the October 7, 2002 OHRP Letter ARDS Network Investigators Response to the October 7, 2002 OHRP Letter March 12, 2003 A. Concerns, questions, and allegations regarding the ARMA trial (ARDSNet Study 01): (1) OHRP is concerned that the

More information

Research Involving Human Subjects: AA 110.7

Research Involving Human Subjects: AA 110.7 Research Involving Human Subjects: AA 110.7 Purpose To set forth certain human subjects rights and protections, and to establish a review process intended to ensure compliance with federal regulations

More information

Lapse in IRB Approval

Lapse in IRB Approval Office for the Protection of Research Subjects (OPRS) Institutional Review Board FWA# 00000083 Lapse in IRB Approval Version: 3.2; Date: 01/05/2016 Approved by: Human Protections Administrator, Director

More information

for Walking with Pedometer Version 2/7/12 Step-by-Step Guide for Explaining Rx & Pedometer

for Walking with Pedometer Version 2/7/12 Step-by-Step Guide for Explaining Rx & Pedometer Key idea Step-by-Step Guide for Explaining Rx & Pedometer Note: Can vary order of sections and expand different points to fit each patient's particular needs and circumstances. Script is illustrated using

More information

Paper prepared by the Secretariat

Paper prepared by the Secretariat COMMISSION FOURTEENTH REGULAR SESSION Manila, Philippines 3 7 December 2017 REFERENCE DOCUMENT FOR REVIEW OF CMM 2005-03 AND FOR THE DEVELOPMENT OF HARVEST STRATEGIES UNDER CMM 2014-06 North Pacific Albacore

More information

Signature Date Date First Effective: Signature Date Revision Date:

Signature Date Date First Effective: Signature Date Revision Date: Revision #10 TITLE: Continuation Review Page 1 of 10 Approved By: ORI Director Signature Date Date First Effective: 05-17-05 Approved By: Nonmedical IRB Chair Signature Date Approved By: Medical IRB Chair

More information

The Effects of Chronic Creatine Supplementation on Performance and Body Composition of Female Athletes. by Megan Brenner

The Effects of Chronic Creatine Supplementation on Performance and Body Composition of Female Athletes. by Megan Brenner The Effects of Chronic Creatine Supplementation on Performance and Body Composition of Female Athletes by Megan Brenner Thesis submitted to the Faculty of Virginia Polytechnic Institute and State University

More information

2019 Canada Winter Games Archery Technical Package

2019 Canada Winter Games Archery Technical Package 2019 Canada Winter Games Archery Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements,

More information

Submitting Continuing Reviews and/or Amendments to the IRB

Submitting Continuing Reviews and/or Amendments to the IRB Submitting Continuing Reviews and/or Amendments to the IRB Tufts-New England Medical Center Tufts University Health Sciences IRB Education Series 2006 Presentation may only be reused or reprinted with

More information

SIERRA-SACRAMENTO VALLEY EMS AGENCY PROGRAM POLICY REFERENCE NO. 474

SIERRA-SACRAMENTO VALLEY EMS AGENCY PROGRAM POLICY REFERENCE NO. 474 SIERRA-SACRAMENTO VALLEY EMS AGENCY PROGRAM POLICY REFERENCE NO. 474 PURPOSE: To establish the requirements and responsibilities of an S-SV approved EMT / Public Safety Automatic External Defibrillation

More information

2011 CANADA WINTER GAMES BOXING TECHNICAL PACKAGE

2011 CANADA WINTER GAMES BOXING TECHNICAL PACKAGE 2011 CANADA WINTER GAMES BOXING TECHNICAL PACKAGE Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements, assist

More information

Version 1. Submission Guide and Policies

Version 1. Submission Guide and Policies Submission Guide and Policies Pearl IRB Investigator Manual Table of Contents 1.1 Pearl IRB overview... 3 1.2 What is the purpose of this manual?... 3 1.3 What is Human Research?... 3 1.4 What is the Human

More information

UNIVERSITY OF IDAHO 4-H MARKET ANIMAL PROJECT POLICY

UNIVERSITY OF IDAHO 4-H MARKET ANIMAL PROJECT POLICY UNIVERSITY OF IDAHO 4-H MARKET ANIMAL PROJECT POLICY 4-H Market Livestock Program Mission Statement. The mission of 4-H is to help youth acquire knowledge, develop life skills, and form attitudes that

More information

Citation for published version (APA): Canudas Romo, V. (2003). Decomposition Methods in Demography Groningen: s.n.

Citation for published version (APA): Canudas Romo, V. (2003). Decomposition Methods in Demography Groningen: s.n. University of Groningen Decomposition Methods in Demography Canudas Romo, Vladimir IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information